
KYNB
Healthcare · Biotechnology · $13.9M market cap
$3.44-0.15 (-4.2%)Nov 13, 4:00 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +1.5% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2026 · upcoming | After the close | -3.66 | -1.61 | +56.0% |
| Aug 13, 2026 | After the close | -3.18 | -4.68 | -47.2% |
| May 11, 2026 | After the close | -3.35 | -3.76 | -12.2% |
| Mar 17, 2026 | Time not confirmed | -3.88 | -3.51 | +9.7% |
| Nov 10, 2025 | After the close | -4.00 | 49.61 | +1340.3% |
| Aug 11, 2025 | After the close | 1.00 | -1.88 | -288.0% |
| May 12, 2025 | After the close | 0.50 | 1.25 | +150.0% |
| Mar 17, 2025 | Time not confirmed | -0.17 | 0.18 | +205.9% |
| Nov 12, 2024 | After the close | -9.50 | 0.37 | +103.9% |
| Aug 6, 2024 | After the close | -6.00 | -4.00 | +33.3% |
| May 6, 2024 | After the close | -13.25 | -8.25 | +37.7% |
| Feb 26, 2024 | Time not confirmed | -0.44 | -0.57 | -29.5% |
| Nov 6, 2023 | After the close | -17.08 |
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl…
| -12.98 |
| +24.0% |
| Aug 7, 2023 | After the close | -18.00 | -22.50 | -25.0% |
| May 8, 2023 | After the close | -18.95 | -20.25 | -6.9% |
| Feb 27, 2023 | Time not confirmed | -0.91 | -0.70 | +23.1% |
| Nov 7, 2022 | After the close | -20.62 | -24.50 | -18.8% |
| Aug 8, 2022 | After the close | -21.31 | -19.50 | +8.5% |
| May 9, 2022 | Time not confirmed | -0.68 | -0.68 | 0.0% |
| Feb 28, 2022 | After the close | -17.50 | -36.25 | -107.1% |
| Nov 9, 2021 | After the close | 12.08 | 13.50 | +11.8% |
| Aug 9, 2021 | After the close | -15.61 | -36.25 | -132.2% |
| May 10, 2021 | After the close | -22.78 | -19.50 | +14.4% |
| Mar 1, 2021 | Time not confirmed | -0.23 | -0.64 | -173.5% |
| Nov 5, 2020 | After the close | -20.14 | 8.75 | +143.4% |
| Aug 6, 2020 | After the close | -19.63 | -23.75 | -21.0% |
| May 7, 2020 | After the close | -11.99 | -22.25 | -85.6% |
| Mar 2, 2020 | Time not confirmed | -0.59 | -1.12 | -89.8% |
| Nov 11, 2019 | After the close | -14.17 | -14.25 | -0.6% |
| Aug 8, 2019 | After the close | -13.79 | 31.50 | +328.4% |
| May 9, 2019 | After the close | -16.55 | -13.25 | +19.9% |
| Feb 28, 2019 | Time not confirmed | — | 5.74 | — |
| Nov 8, 2018 | After the close | -10.92 | -12.50 | -14.5% |
| Aug 7, 2018 | After the close | -14.78 | -7.00 | +52.6% |
| May 9, 2018 | After the close | -12.77 | -12.50 | +2.1% |
| Feb 28, 2018 | Time not confirmed | — | -6.73 | — |